4,800 Gene Comprehensive Panel Expands, Streamlines, and Simplifies Sequencing Portfolios
SAN DIEGO--(BUSINESS WIRE)--Oct. 7, 2013-- Illumina, Inc. (NASDAQ:ILMN) today announced the launch of the TruSight One Sequencing Panel, the industry’s broadest sequencing panel that targets 4,813 genes with known associated clinical phenotypes. Clinical research laboratories can use this panel to expand existing menus, streamline workflows, or create an entire portfolio of sequencing options, with benefits including increased productivity, reduced handling errors, and decreased costs.
The power of the TruSight One Sequencing Panel is enhanced by Illumina’s user-friendly VariantStudio analysis and reporting software. To coincide with the introduction of the TruSight One Sequencing Panel, VariantStudio will offer new features that expand annotation and filtering capabilities. These features include support for enabling family-based filtering (mother, father, child, and siblings), providing variant classifications, and generating ready-to-use reports. In addition, the TruSight One Sequencing Panel can be used to create dozens of “virtual subpanels” to fit the needs of any clinical researcher seeking to understand the genetic basis of disease.
“Illumina is moving in the direction of one simple workflow which will drastically reduce the turnaround time from sample-to-report,” said Matt Posard, Senior Vice President and General Manager of Illumina’s Translational and Consumer Genomics business. “With the TruSight One Sequencing Panel and enhancements to VariantStudio, Illumina is providing clinical researchers with a simple, cost-effective solution that replaces small sequencing panels with a single robust platform.”
“Our genetics laboratory handles increasing numbers of requests to sequence a wide range of genes believed to be causing inherited disorders,” said Stephen Abbs, Director of Genetics Laboratories, Cambridge University Hospitals NHS Foundation Trust. “The broad coverage and high performance of the TruSight One Sequencing Panel allow us to perform these analyses using a streamlined laboratory workflow, as well as to offer a comprehensive, high-quality sequencing service.”
The TruSight One Sequencing Panel is now shipping. For more information, visit www.illumina.com/PowerOfOne.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com
